Relaxin as a cardiovascular drug: a promise kept
- PMID: 22424540
- DOI: 10.2174/157488611798918719
Relaxin as a cardiovascular drug: a promise kept
Abstract
Relaxin (RLX), formerly known for its effects on reproduction and pregnancy, has been later shown to be a pleiotropic hormone, capable of also targeting numerous non-reproductive organs of the cardiovascular, nervous, respiratory, tegumental, excretory and digestive systems. Most of these effects have been studied in animal models, but there is compelling evidence that RLX also acts in humans. In more recent years, human luteal-type (H2) RLX synthesised by recombinant DNA technology has been investigated in clinical trials, mostly oriented to assess its therapeutic potential in cardiovascular disease. This indication was based on the accumulating pre-clinical evidence that RLX possesses prominent biological effects on systemic and coronary blood vessels, cardiomyocyte growth and differentiation, and cardiac/vascular connective tissue remodelling. This mini-review was intended as an update of our previous article that appeared in this journal in 2009, as the last 2 years have been characterised by fundamental achievements on the clinical profile of RLX. Eventually, after many years of inconclusive studies, RLX appears to be about to reach a recognised dignity as a cardiovascular drug.
Similar articles
-
Clinical profile of relaxin, a possible new drug for human use.Curr Drug Saf. 2009 Sep;4(3):238-49. doi: 10.2174/157488609789006967. Epub 2009 Sep 1. Curr Drug Saf. 2009. PMID: 19534649 Review.
-
Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.Drug Discov Today. 2020 Jul;25(7):1239-1244. doi: 10.1016/j.drudis.2020.04.014. Epub 2020 Apr 29. Drug Discov Today. 2020. PMID: 32360533 Review.
-
Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration.J Cell Mol Med. 2012 Mar;16(3):507-19. doi: 10.1111/j.1582-4934.2011.01328.x. J Cell Mol Med. 2012. PMID: 21554533 Free PMC article.
-
Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises.Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):101-8. doi: 10.2174/187152507780363179. Cardiovasc Hematol Agents Med Chem. 2007. PMID: 17430134 Review.
-
Relaxin' the Heart: A Novel Therapeutic Modality.J Cardiovasc Pharmacol Ther. 2016 Jul;21(4):353-62. doi: 10.1177/1074248415617851. Epub 2015 Nov 20. J Cardiovasc Pharmacol Ther. 2016. PMID: 26589290 Review.
Cited by
-
Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis.J Endocrinol Invest. 2014 Jun;37(6):559-64. doi: 10.1007/s40618-014-0068-7. Epub 2014 Apr 11. J Endocrinol Invest. 2014. PMID: 24729283
-
Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis.Acta Pharmacol Sin. 2018 Jul;39(7):1243-1248. doi: 10.1038/aps.2018.8. Epub 2018 Mar 22. Acta Pharmacol Sin. 2018. PMID: 29565035 Free PMC article.
-
Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.PLoS One. 2013 May 21;8(5):e63896. doi: 10.1371/journal.pone.0063896. Print 2013. PLoS One. 2013. PMID: 23704950 Free PMC article.
-
Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury.J Cell Mol Med. 2013 Nov;17(11):1494-505. doi: 10.1111/jcmm.12120. Epub 2013 Sep 20. J Cell Mol Med. 2013. PMID: 24079335 Free PMC article.
-
Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.J Clin Hypertens (Greenwich). 2013 May;15(5):333-6. doi: 10.1111/jch.12075. Epub 2013 Feb 12. J Clin Hypertens (Greenwich). 2013. PMID: 23614848 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
